Perspective Therapeutics (CATX) Other Non-Current Assets (2011 - 2026)
Perspective Therapeutics' (CATX) quarterly Other Non-Current Assets came in at $509000.0 in Q2 2026, up 26.93% year-over-year from $401000.0 in Q2 2025, and up 3.88% quarter-over-quarter from $490000.0 in Q1 2026.
Powered by 
Analysis
Perspective Therapeutics (CATX) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Other Non-Current Assets across 16 years of filings, most recently posting $509000.0 for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 26.93% year-over-year to $509000.0; the TTM figure through Jun 2026 stood at $509000.0 (up 26.93% YoY), while the FY2025 annual figure was $486000.0, up 20.0% from the prior year.
- Other Non-Current Assets came in at $509000.0 for Q2 2026 at Perspective Therapeutics, up from $490000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.3 million in Q4 2023 to a low of $182000.0 in Q1 2022.
- Average Other Non-Current Assets over 5 years is $816333.3, with a median of $383500.0 recorded in 2025.
- Year-over-year, Other Non-Current Assets soared 2179.12% in 2022 and slumped 92.36% in 2024.
- Over 5 years, Other Non-Current Assets stood at $4.1 million in 2022, then increased by 27.8% to $5.3 million in 2023, then plunged by 92.36% to $405000.0 in 2024, then grew by 20.0% to $486000.0 in 2025, then climbed by 4.73% to $509000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $509000.0 in Q2 2026, $490000.0 in Q1 2026, and $486000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | 509,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 509,000.00 |
| Mar 31, 2026 | 490,000.00 |
| Dec 31, 2025 | 486,000.00 |
| Sep 30, 2025 | 438,000.00 |
| Jun 30, 2025 | 401,000.00 |
| Mar 31, 2025 | 366,000.00 |
| Dec 31, 2024 | 405,000.00 |
| Sep 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 5.30 Mn |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 182,000.00 |
| Mar 31, 2023 | 182,000.00 |
| Dec 31, 2022 | 4.15 Mn |
| Sep 30, 2022 | 182,000.00 |
| Jun 30, 2022 | 182,000.00 |
| Mar 31, 2022 | 182,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 182,000.00 |